T80.319S ABO incompatibility with hemolytic transfusion reaction, unspecified, sequela

Name of the Condition

• ABO incompatibility with hemolytic transfusion reaction, unspecified, sequela.

Summary

This condition represents a sequela (late effect) of a hemolytic transfusion reaction due to ABO incompatibility. It describes residual or chronic effects resulting from the initial immune-mediated destruction of red blood cells during an incompatible transfusion. The sequela may involve ongoing complications or long-term consequences of the original reaction, such as organ damage or persistent hemolysis.

Causes

ABO incompatibility reactions stem from transfusing blood or blood products with ABO antigens that do not match the recipient's blood type. This mismatch triggers an immune response, where the recipient's antibodies bind to donor red blood cells, causing their destruction (hemolysis). The sequela arises as a late effect of this initial reaction, reflecting persistent or residual damage from the original event.

Risk Factors

• Transfusion of blood products without proper ABO typing or crossmatching
• Emergency transfusions where typing may be delayed
• Human error in blood product labeling or administration
• Use of pooled plasma products with mixed ABO types
• Transfusion of platelets or plasma from donors with incompatible ABO antigens

Symptoms

• Persistent fatigue or weakness
• Jaundice (yellowing of skin or eyes)
• Dark urine (hemoglobinuria)
• Abdominal pain or discomfort
• Unexplained anemia

Diagnosis

Diagnosis involves reviewing the patient's transfusion history and identifying residual effects consistent with a prior hemolytic reaction. Laboratory tests may show signs of ongoing hemolysis, such as elevated bilirubin, low haptoglobin, or reticulocytosis. Imaging or other studies may be used to assess organ damage if complications are suspected.

Treatment Options

Treatment focuses on managing residual symptoms and preventing further complications. This may include monitoring for anemia, addressing organ dysfunction, and avoiding future incompatible transfusions. Supportive care, such as blood transfusions or medications, may be used as needed based on the severity of the sequela.

Prognosis and Follow-Up

Prognosis depends on the extent of initial damage and the effectiveness of management. Regular follow-up is important to monitor for late complications, such as renal impairment or chronic anemia. Long-term outcomes vary, with some patients experiencing full recovery and others having persistent effects.

Complications

• Chronic kidney disease or renal failure
• Persistent anemia requiring ongoing treatment
• Jaundice or bilirubin-related issues
• Increased risk of future transfusion reactions
• Organ damage from the initial hemolysis

Lifestyle & Prevention

• Ensure all future transfusions are ABO-compatible
• Maintain clear communication with healthcare providers about transfusion history
• Follow up regularly to monitor for late effects
• Avoid unnecessary transfusions when possible
• Report any new symptoms to a healthcare provider promptly

When to Seek Professional Help

Seek immediate medical attention if you experience severe symptoms such as chest pain, difficulty breathing, or signs of shock. Contact your healthcare provider for persistent fatigue, jaundice, or unexplained anemia, especially if you have a history of transfusion reactions.

Tips for Medical Coders

Document the sequela clearly, linking it to the original ABO incompatibility event. Ensure the medical record supports the residual effects and their relationship to the prior hemolytic transfusion reaction. Code T80.319S is appropriate when the sequela is the focus of care, with documentation confirming the late effect of the initial reaction.